• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用阿布昔替尼治疗难治性毛发红糠疹。

Refractory pityriasis rubra pilaris treated with abrocitinib.

作者信息

Rob Filip

机构信息

Department of Dermatovenerology, Second Faculty of Medicine, Charles University, Bulovka University Hospital, Prague.

出版信息

Dermatol Reports. 2025 Aug 22;17(3). doi: 10.4081/dr.2025.10105. Epub 2025 Jan 9.

DOI:10.4081/dr.2025.10105
PMID:40844385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12421531/
Abstract

Pityriasis rubra pilaris is a rare idiopathic papulosquamous disorder that significantly impacts quality of life and is often refractory to conventional therapies. This study presents a case of successful treatment with an abrocitinib JAK1 inhibitor after several conventional and biologic therapies failed.

摘要

红皮病型毛发红糠疹是一种罕见的特发性丘疹鳞屑性疾病，严重影响生活质量，且通常对传统疗法难治。本研究介绍了一例在多种传统疗法和生物疗法失败后，使用阿布昔替尼JAK1抑制剂成功治疗的病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9697/12421531/be8b9aa14c99/dr-17-3-10105-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9697/12421531/5ea3655b06f6/dr-17-3-10105-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9697/12421531/be8b9aa14c99/dr-17-3-10105-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9697/12421531/5ea3655b06f6/dr-17-3-10105-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9697/12421531/be8b9aa14c99/dr-17-3-10105-g002.jpg

相似文献

1
Refractory pityriasis rubra pilaris treated with abrocitinib.用阿布昔替尼治疗难治性毛发红糠疹。
Dermatol Reports. 2025 Aug 22;17(3). doi: 10.4081/dr.2025.10105. Epub 2025 Jan 9.
2
Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris-A systematic review.小分子药物治疗毛发红糠疹的疗效与安全性——一项系统评价
Front Med (Lausanne). 2025 Feb 25;12:1544197. doi: 10.3389/fmed.2025.1544197. eCollection 2025.
3
A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists.一项关于 TNF 拮抗剂治疗 1 型毛发红糠疹的文献系统回顾。
J Eur Acad Dermatol Venereol. 2013 Jan;27(1):e131-5. doi: 10.1111/j.1468-3083.2012.04456.x. Epub 2012 Feb 10.
4
Case Report: Successful treatment of a novel variant of -mutated juvenile Pityriasis rubra pilaris with ixekizumab.病例报告：用司库奇尤单抗成功治疗一例新型 - 突变型青少年毛发红糠疹。
Front Med (Lausanne). 2025 Jul 22;12:1637045. doi: 10.3389/fmed.2025.1637045. eCollection 2025.
5
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
6
A case of classic adult pityriasis rubra pilaris successfully treated with a combination of acitretin and ustekinumab: A case report.一例联合使用阿维A和乌司奴单抗成功治疗的经典型成人毛发红糠疹：病例报告
SAGE Open Med Case Rep. 2022 Apr 19;10:2050313X221093453. doi: 10.1177/2050313X221093453. eCollection 2022.
7
Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: A case report and literature review.司库奇尤单抗单药疗法成功治疗重度难治性V型（非典型青少年型）毛发红糠疹：一例报告及文献综述
Dermatol Ther. 2020 Nov;33(6):e14097. doi: 10.1111/dth.14097. Epub 2020 Sep 4.
8
Targeting IL-1 controls refractory pityriasis rubra pilaris.针对白细胞介素-1 可控制难治性毛发红糠疹。
Sci Adv. 2024 Jul 5;10(27):eado2365. doi: 10.1126/sciadv.ado2365. Epub 2024 Jul 3.
9
Use of Biologics in Pityriasis Rubra Pilaris Refractory to First-Line Systemic Therapy: A Systematic Review [Formula: see text].生物制剂在一线全身治疗难治性红皮病性银屑病中的应用：系统评价[公式：见正文]。
J Cutan Med Surg. 2020 Jan/Feb;24(1):73-78. doi: 10.1177/1203475419887731. Epub 2019 Nov 6.
10
Prescription of Controlled Substances: Benefits and Risks管制药品的处方：益处与风险

本文引用的文献

1
Efficacy and safety of oral abrocitinib monotherapy in pityriasis rubra pilaris.口服阿布昔替尼单药治疗毛发红糠疹的疗效和安全性。
J Eur Acad Dermatol Venereol. 2024 Nov;38(11):e920-e922. doi: 10.1111/jdv.19992. Epub 2024 Mar 30.
2
Biologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review.用于治疗毛发红糠疹的生物制剂：文献综述
J Cutan Med Surg. 2024 May-Jun;28(3):269-275. doi: 10.1177/12034754241238735. Epub 2024 Mar 28.
3
Pityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options.
红癣：临床特征、发病机制及治疗选择的最新综述。
Am J Clin Dermatol. 2024 Mar;25(2):243-259. doi: 10.1007/s40257-023-00836-x. Epub 2023 Dec 30.
4
Successful treatment of erythrodermic pityriasis rubra pilaris with upadacitinib.乌帕替尼成功治疗红皮病型毛发红糠疹
J Eur Acad Dermatol Venereol. 2024 Jul;38(7):e593-e595. doi: 10.1111/jdv.19762. Epub 2023 Dec 16.
5
The Effectiveness of Anti-Interleukin-17A Treatment for Pityriasis Rubra Pilaris: A Systematic Review.抗白细胞介素-17A治疗毛发红糠疹的有效性：一项系统评价。
Cureus. 2023 Jun 29;15(6):e41125. doi: 10.7759/cureus.41125. eCollection 2023 Jun.
6
A case of pityriasis rubra pilaris treated with tofacitinib after failure with acitretin and ixekizumab.一例阿维A和司库奇尤单抗治疗失败后用托法替布治疗的红皮病型毛发红糠疹病例。
Australas J Dermatol. 2023 Aug;64(3):445-447. doi: 10.1111/ajd.14076. Epub 2023 May 18.
7
Refractory pityriasis rubra pilaris treated with upadacitinib.用乌帕替尼治疗难治性毛发红糠疹。
JAAD Case Rep. 2023 Mar 15;35:112-114. doi: 10.1016/j.jdcr.2023.03.004. eCollection 2023 May.
8
Pityriasis rubra pilaris partially responsive to treatment with upadacitinib: A case report.对乌帕替尼治疗部分反应的红皮病性毛发红糠疹：一例报告
SAGE Open Med Case Rep. 2023 Mar 29;11:2050313X231160927. doi: 10.1177/2050313X231160927. eCollection 2023.
9
A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring.JAK抑制剂在皮肤病学中应用的安全性综述：临床与实验室监测
Dermatol Ther (Heidelb). 2023 Mar;13(3):729-749. doi: 10.1007/s13555-023-00892-5. Epub 2023 Feb 15.
10
Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris.红皮病型毛发红糠疹中与精神症状及生活质量受损相关的患者和疾病特征。
Br J Dermatol. 2022 Dec;187(6):1024-1026. doi: 10.1111/bjd.21792. Epub 2022 Aug 18.